No abstract

No abstract

The continuous development of new active pharmaceutical ingredients (API) that are moisture sensitive, made roller compaction more popular, and thus encourages research into the different processing parameters whose modification may enhance the production of roller compactors. The Alexanderwerk WP120 is a roller compactor with an integrated two-stage mill that is used for small/medium scale batch manufacture. This study was carried out to determine the impact of upper mesh size of the integrated mill of the Alexanderwerk WP120 roller compactor on granule PSD, flow and compactability. The results showed that the upper mesh size may have a significant effect on PSD of lower solid fraction ribbon/wafer (≤ 0.65SF). However, these differences in PSD may not be sufficient to afford a significant change in bulk powder flow and compactability properties.

<p class="abstract"><strong>Background:</strong> Public awareness about the importance of clinical research (CR) is crucial for patient’s participation in clinical trials. Their enrollment may be impacted by their levels of awareness and attitudes toward participation. Our study aimed to assess the Saudi cancer patient’s knowledge and perception about CR, and determine the influencing factors and barriers affecting participation.</p><p class="abstract"><strong>Methods:</strong> A cross-sectional study was conducted in 300 cancer patients attending the Oncology Department at King AbdulAziz Medical City (KAMC) Riyadh between February 2011 and February 2012 using a survey covering the demographic data, knowledge of clinical research, and attitude toward participation; followed by statistical analysis.</p><p class="abstract"><strong>Results:</strong> A total of 300 patients were enrolled in the study with a median age of 53.6 (42.2-64.01); 62.67% of which were females. The majority of patients (97.31%) were not aware of Institutional Review Board (IRB). However, (75.33%) showed interest in CR participation, if offered. The advanced disease (86.67%), and the lack of other treatment options (85.33%) were the top two encouraging factors, while fear of adverse side effects (58.33%), and the unknown efficacy of treatment (58.32%) were the top two barriers against participation. Respondents younger than 45 years, and educated ones were significantly more interested in participation in CR with P values P=0.0136 and P=0.0239 respectively.</p><p class="abstract"><strong>Conclusions: </strong>There is an apparent gap in cancer patient’s awareness about CR. However, there is an obvious interest in participation in CR especially in younger and educated patients. Enhancing public awareness is crucial to improve participation in CR.</p>